<DOC>
	<DOCNO>NCT01584531</DOCNO>
	<brief_summary>The primary objective study determine rigosertib sodium , give orally form soft gel capsule , safe associate reduction number blood transfusion unit need patient myelodysplastic syndrome ( MDS ) classify Low Intermediate-1 ( Int-1 ) ( cytogenetics ) trisomy 8 Intermediate 2 ( Int-2 ) International Prognostic Scoring System ( IPSS ) transfusion-dependent . Rigosertib take day 1 21 21-day cycle .</brief_summary>
	<brief_title>Efficacy Safety Oral Rigosertib Transfusion-dependent , Low Int-1 Trisomy 8 Int-2 Myelodysplastic Syndrome</brief_title>
	<detailed_description>This Phase II open-label , multicenter ( 5 center ) , single-arm study . Sixty transfusion-dependent patient MDS classify Low Int-1 risk ( cytogenetics ) trisomy 8 Int-2 International Prognostic Scoring System ( IPSS ) enrol receive rigosertib BID 21 consecutive day 21-day cycle . Patients stratify prior treatment azacitidine and/or decitabine and/or lenalidomide and/or erythropoietin . Patients remain treated study 2006 Internation Working Group ( IWG ) progression criterion meet death cause . All study participant allow , medically justified , access RBC platelet transfusion , filgrastim [ G-CSF ] . Erythropoiesis-stimulating agent ( ESAs ) allow initial 3 cycle . Rigosertib dose adjustment policy describe Protocol .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Trisomy</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Diagnosis MDS confirm bone marrow aspirate and/or biopsy within 6 week prior first dose study drug accord World Health Organization ( WHO ) FrenchAmericanBritish ( FAB ) classification MDS classify Low risk Int1 risk ( cytogenetics ) Trisomy 8 Int2 risk , accord IPSS classification Transfusion dependency define least 4 unit RBC administer within 8 week baseline Off treatment MDS ( azacitidine , decitabine , lenalidomide , chemotherapy , immunosuppressive agent ) least 4 week ECOG performance status 0 , 1 2 Ongoing clinically significant anemia due factor iron , B12 , folate deficiency , autoimmune hereditary hemolysis , gastrointestinal ( GI ) bleeding , unless stabilize 1 week RBC transfusion Serum ferritin &lt; 50 ng/mL Hypoplastic MDS ( cellularity &lt; 10 % ) Any active malignancy within past year , except basal cell squamous cell skin cancer carcinoma situ cervix breast Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Active infection adequately respond appropriate therapy Total bilirubin ≥1.5 mg/dL relate hemolysis Gilbert 's disease ALT/AST ≥2.5 x upper limit normal ( ULN ) Serum creatinine ≥2.0 mg/dL Ascites require active medical management include paracentesis Hyponatremia ( define serum sodium value &lt; 130 mEq/L ) Female patient pregnant lactate Patients unwilling follow strict contraception requirement Female patient reproductive potential negative urine betahuman chorionic gonadotropin ( bHCG ) pregnancy test Screening Major surgery without full recovery major surgery within 3 week rigosertib treatment start Uncontrolled hypertension ( define systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg ) New onset seizure ( within 3 month prior first dose rigosertib ) poorly control seizures Any concurrent investigational agent chemotherapy , radiotherapy , immunotherapy Chronic use ( &gt; 2 week ) corticosteroid ( &gt; 10 mg/24 hr equivalent prednisone ) within 4 week start rigosertib Investigational therapy within 4 week start rigosertib Psychiatric illness social situation would limit patient 's ability tolerate and/or comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>rigosertib sodium</keyword>
	<keyword>rigosertib</keyword>
	<keyword>ON 01910.Na</keyword>
	<keyword>oral rigosertib</keyword>
</DOC>